当前位置: 首页 >> 检索结果
共有 5106 条符合本次的查询结果, 用时 2.3025731 秒

3401. Endovascular repair of abdominal and thoracic aortic aneurysms.

作者: Barry T Katzen.;Michael D Dake.;Alexandra A MacLean.;David S Wang.
来源: Circulation. 2005年112卷11期1663-75页

3402. Epidemiology of uncontrolled hypertension in the United States.

作者: Thomas J Wang.;Ramachandran S Vasan.
来源: Circulation. 2005年112卷11期1651-62页

3403. Blood pressure lowering in PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and white matter hyperintensities: should this progress matter to patients?

作者: Ernesto L Schiffrin.
来源: Circulation. 2005年112卷11期1525-6页

3404. Cell therapy for angiogenesis: embracing diversity.

作者: Rajiv Gulati.;Robert D Simari.
来源: Circulation. 2005年112卷11期1522-4页

3405. Risk stratification in pulmonary embolism based on biomarkers and echocardiography.

作者: Evangelos Giannitsis.;Hugo A Katus.
来源: Circulation. 2005年112卷11期1520-1页

3406. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

作者: Scott M Grundy.;James I Cleeman.;Stephen R Daniels.;Karen A Donato.;Robert H Eckel.;Barry A Franklin.;David J Gordon.;Ronald M Krauss.;Peter J Savage.;Sidney C Smith.;John A Spertus.;Fernando Costa.; .; .
来源: Circulation. 2005年112卷17期2735-52页

3407. Is surgery preferred for the diabetic with multivessel disease? Debate on revascularization strategy for diabetic patients with multivessel coronary artery disease.

作者: George Dangas.;Jeffrey W Moses.
来源: Circulation. 2005年112卷10期1507-13; discussion 1514页

3408. Is surgery preferred for the diabetic with multivessel disease? Surgery is preferred for the diabetic with multivessel disease.

作者: Spencer B King.
来源: Circulation. 2005年112卷10期1500-7; discussion 1514-5页

3409. Diuretics for hypertension.

作者: Lawrence R Krakoff.
来源: Circulation. 2005年112卷10期e127-9页

3410. Renovascular hypertension and ischemic nephropathy.

作者: Vesna D Garovic.;Stephen C Textor.
来源: Circulation. 2005年112卷9期1362-74页

3411. Should atrial fibrillation ablation be considered first-line therapy for some patients? Should ablation be first-line therapy and for whom? the antagonist position.

作者: Benzy J Padanilam.;Eric N Prystowsky.
来源: Circulation. 2005年112卷8期1223-9; discussion 1230页

3412. The dynamics of cardiac fibrillation.

作者: James N Weiss.;Zhilin Qu.;Peng-Sheng Chen.;Shien-Fong Lin.;Hrayr S Karagueuzian.;Hideki Hayashi.;Alan Garfinkel.;Alain Karma.
来源: Circulation. 2005年112卷8期1232-40页
Reentry occurs when the electrical wave propagating through the atria or ventricles breaks locally and forms a rotor (also called a scroll wave or functional reentry). If the waves propagating outward from a rotor develop additional wavebreaks (which may form new rotors), fibrillation results. Tissue heterogeneity, exacerbated by electrical and structural remodeling from cardiac disease, has traditionally been considered the major factor promoting wavebreak and its degeneration to fibrillation. Recently, however, dynamic factors have also been recognized to play a key role. Dynamic factors refer to cellular properties of the cardiac action potential and Ca(i) cycling, which dynamically generate wave instability and wavebreak, even in tissue that is initially completely homogeneous. Although the latter situation can only be created in computer simulations, its relevance to real (heterogeneous) cardiac tissue has been unequivocally demonstrated. Dynamic factors are related to membrane voltage (Vm) and Ca(i). Vm factors include electrical restitution of action potential duration and conduction velocity, short-term cardiac memory, and electrotonic currents. Ca(i) factors are related to dynamic Ca(i) cycling properties. They act synergistically, as well as with tissue heterogeneity, to promote wavebreak and fibrillation. As global properties, rather than local electrophysiological characteristics, dynamic factors represent an attractive target for novel therapies to prevent ventricular fibrillation.

3413. Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients.

作者: Atul Verma.;Andrea Natale.
来源: Circulation. 2005年112卷8期1214-22; discussion 1231页

3414. 'Atrial fibrillation--an end to the epidemic?'.

作者: John Camm.
来源: Circulation. 2005年112卷8期iii页

3415. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine.

作者: Domenico Praticò.;Jean-Michel Dogné.
来源: Circulation. 2005年112卷7期1073-9页

3416. Patent foramen ovale and stroke.

作者: Shunichi Homma.;Ralph L Sacco.
来源: Circulation. 2005年112卷7期1063-72页

3417. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review.

作者: J A Iestra.;D Kromhout.;Y T van der Schouw.;D E Grobbee.;H C Boshuizen.;W A van Staveren.
来源: Circulation. 2005年112卷6期924-34页
Guidelines for lifestyle and dietary modification in patients with coronary artery disease (CAD) are mainly supported by evidence from general population studies. CAD patients, however, differ from the general population in age (older) and treatment with preventive drugs. This review seeks to provide evidence for a prognostic benefit of lifestyle and dietary recommendations from studies in CAD patients.

3418. Sleep and hypertension: a challenge for the autonomic regulation of the cardiovascular system.

作者: Jacopo M Legramante.;Alberto Galante.
来源: Circulation. 2005年112卷6期786-8页

3419. Cyclooxygenase inhibition and cardiovascular risk.

作者: Elliott M Antman.;David DeMets.;Joseph Loscalzo.
来源: Circulation. 2005年112卷5期759-70页

3420. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts.

作者: Robert A Levine.;Ehud Schwammenthal.
来源: Circulation. 2005年112卷5期745-58页
共有 5106 条符合本次的查询结果, 用时 2.3025731 秒